An Informational Webinar with Larimar Therapeutics — March 20, 2026

On March 20, 2026, Russell Clayton, DO, Chief Medical Officer at Larimar Therapeutics, shared updates about the nomlabofusp clinical program including information about opportunities for children, adolescents, and adults to enroll in the open label study as well as the upcoming phase 3 study. _________________________________ FARA's Mission is to marshal and focus the resources and relationships needed to cure Friedreich's Ataxia (FA) by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases. Friedreich’s Ataxia is a debilitating, life-shortening, degenerative neuro-muscular disorder. About one in 50,000 people in the United States have Friedreich's Ataxia. Subscribe to FARA's YouTube channel    / fara1998   Follow FARA on Facebook   / curefa   Follow FARA on Instagram   / curefa_org